Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELEV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELEVElevation Oncology$0.32+5.6%$0.31$0.22▼$4.06$18.77M1.591.38 million shs288,256 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELEVElevation Oncology0.00%-3.33%-12.80%-36.28%-92.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELEVElevation Oncology2.6691 of 5 stars4.22.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELEVElevation Oncology 2.30Hold$3.39968.05% UpsideCurrent Analyst Ratings BreakdownLatest ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ELEVElevation OncologyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $1.003/21/2025ELEVElevation OncologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/21/2025ELEVElevation OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$10.00 ➝ $0.703/21/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $1.003/20/2025ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025ELEVElevation OncologyLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/10/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/7/2025ELEVElevation OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELEVElevation Oncology-$45.70M-$0.82N/AN/AN/AN/A-59.73%-40.05%8/5/2025 (Estimated)Latest ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ELEVElevation Oncology-$0.20-$0.24-$0.04-$0.24N/AN/A3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELEVElevation OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELEVElevation Oncology0.4517.7717.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELEVElevation Oncology83.70%Insider OwnershipCompanyInsider OwnershipELEVElevation Oncology8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELEVElevation Oncology4059.22 million54.33 millionOptionableELEV HeadlinesRecent News About These CompaniesElevation Oncology Reports Q1 2025 Financial ResultsMay 17, 2025 | tipranks.comElevation Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 15, 2025 | prnewswire.comElevation Oncology reveals promising ADC data for solid tumorsApril 27, 2025 | uk.investing.comElevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025April 25, 2025 | prnewswire.comElevation Oncology (ELEV) Gets a Hold from Leerink PartnersApril 19, 2025 | markets.businessinsider.comGSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotechApril 18, 2025 | biopharmadive.comElevation Mulls Strategic Alternatives, Including Closure, Amid Activist PressureApril 18, 2025 | biospace.comElevation is latest biotech to face activist investor demands to wind downApril 17, 2025 | fiercebiotech.comElevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | prnewswire.comStephens & Co. Downgrades Elevation Oncology (ELEV)March 25, 2025 | msn.comElevation Oncology Terminates CLDN18.2-Targeted ADC, Reduces WorkforceMarch 24, 2025 | precisionmedicineonline.comElevation Oncology downgraded to Equal Weight from Overweight at StephensMarch 24, 2025 | markets.businessinsider.comElevation Oncology to discontinue development of EO-3021, a Claudin 18.2 ADC to treat advanced unresectable or metastatic gastric and GEJMarch 22, 2025 | pharmabiz.comCitizens Capital Markets Downgrades Elevation Oncology (ELEV)March 22, 2025 | msn.comLeerink Partners Downgrades Elevation Oncology (ELEV)March 21, 2025 | msn.comElevation Oncology downgraded to Market Perform from Outperform at Citizens JMPMarch 21, 2025 | markets.businessinsider.comElevation Oncology price target lowered to $1 from $6 at H.C. WainwrightMarch 21, 2025 | markets.businessinsider.comElevation Oncology Plunges 42% on Ending Development of Lead DrugMarch 21, 2025 | zacks.comElevation Oncology (NASDAQ:ELEV) Stock, Short Interest ReportMarch 21, 2025 | benzinga.comElevation Oncology downgraded as it halts lead asset on disappointing trialsMarch 21, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodRecession Prep: Consumer Staples are BackBy Jeffrey Neal Johnson | May 5, 2025View Recession Prep: Consumer Staples are BackD-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?By Nathan Reiff | May 28, 2025View D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?ELEV Company DescriptionsElevation Oncology NASDAQ:ELEV$0.32 +0.02 (+5.63%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Why Dollar General May Be Retail’s Most Undervalued Rebound Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
